Literature DB >> 17393957

Update on the use of antiplatelet agents in secondary stroke prevention.

Dara G Jamieson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17393957      PMCID： PMC2569636     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN： 0027-9684            Impact factor:   1.798


× No keyword cloud information.
  8 in total

1.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.

Authors:  Ralph L Sacco; Robert Adams; Greg Albers; Mark J Alberts; Oscar Benavente; Karen Furie; Larry B Goldstein; Philip Gorelick; Jonathan Halperin; Robert Harbaugh; S Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J Kenton; Michael Marks; Lee H Schwamm; Thomas Tomsick
Journal:  Stroke       Date:  2006-02       Impact factor: 7.914

2.  National Stroke Association guidelines for the management of transient ischemic attacks.

Authors:  S Claiborne Johnston; Mai N Nguyen-Huynh; Miriam E Schwarz; Kate Fuller; Christina E Williams; S Andrew Josephson; Graeme J Hankey; Robert G Hart; Steven R Levine; Jose Biller; Robert D Brown; Ralph L Sacco; L Jaap Kappelle; Peter J Koudstaal; Julien Bogousslavsky; Louis R Caplan; Jan van Gijn; Ale Algra; Peter M Rothwell; Harold P Adams; Gregory W Albers
Journal:  Ann Neurol       Date:  2006-09       Impact factor: 10.422

3.  European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

Authors:  H C Diener; L Cunha; C Forbes; J Sivenius; P Smets; A Lowenthal
Journal:  J Neurol Sci       Date:  1996-11       Impact factor: 3.181

4.  Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

Authors:  P H A Halkes; J van Gijn; L J Kappelle; P J Koudstaal; A Algra
Journal:  Lancet       Date:  2006-05-20       Impact factor: 79.321

Review 5.  Antiplatelet therapy in populations at high risk of atherothrombosis.

Authors:  David P Faxon; Richard W Nesto
Journal:  J Natl Med Assoc       Date:  2006-05       Impact factor: 1.798

Review 6.  Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Gregory W Albers; Pierre Amarenco; J Donald Easton; Ralph L Sacco; Philip Teal
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Authors:  Deepak L Bhatt; Keith A A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Danielle M Brennan; Liz Fabry-Ribaudo; Joan Booth; Eric J Topol
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

8.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Julien Bogousslavsky; Lawrence M Brass; Claudio Cimminiello; Laszlo Csiba; Markku Kaste; Didier Leys; Jordi Matias-Guiu; Hans-Jürgen Rupprecht
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.